Suvorexant belongs to a new class of sleep medications called dual orexin receptor antagonists. Orexin is a molecule that promotes wakefulness; suvorexant blocks it, promoting deeper sleep.

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

If drugs could be developed to prevent orexin from binding to its receptors, Mignot thought, then people with insomnia would become “narcoleptic for one night”. In 2007, researchers at the ...

The use of AI in sleep medicine continues to evolve, said D’Ambrosio. She cited a recent review in the Journal of Clinical ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

Belsomra (suvorexant) is an FDA-approved medication for insomnia (a sleep disorder). People also use it for insomnia in people with Alzheimer's disease. Belsomra prevents the orexin A and B ...